Antiviral Drugs - Angola

Angola

The revenue in the Antiviral Drugs market in Angola is estimated to reach US$10.31m in 2024.
It is anticipated that the market will experience a compound annual growth rate (CAGR 2024-2029) of 1.71%, leading to a market volume of US$11.22m by 2029.
When compared globally, United States is expected to generate the highest revenue, projected to be US$30,640.00m in 2024.
Angola is experiencing a surge in demand for antiviral drugs due to the increasing prevalence of infectious diseases in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for antiviral drugs in Angola has been steadily increasing over the past few years.

Customer preferences: Customers in Angola are increasingly looking for antiviral drugs that are effective in treating a wide range of viral infections. They are also looking for drugs that are affordable and easily accessible.

Trends in the market: One of the biggest trends in the antiviral drugs market in Angola is the increasing prevalence of viral infections such as HIV/AIDS, hepatitis, and influenza. This has led to a growing demand for antiviral drugs that can effectively treat these infections. Another trend is the growing availability of generic antiviral drugs, which are more affordable than their branded counterparts.

Local special circumstances: Angola has a high prevalence of HIV/AIDS, with an estimated 310,000 people living with the disease. This has led to a high demand for antiviral drugs that can effectively treat HIV/AIDS. Additionally, Angola has a high incidence of hepatitis B and C, which has further driven the demand for antiviral drugs.

Underlying macroeconomic factors: Angola is one of the fastest-growing economies in Africa, with a GDP growth rate of 2.2% in 2019. This has led to an increase in disposable income and healthcare spending, which has in turn driven the demand for antiviral drugs. However, the country still faces challenges such as a lack of healthcare infrastructure and a shortage of healthcare professionals, which could limit the growth of the antiviral drugs market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.